Clinical trial
Evaluation of Manufacturing Lot of StaphVAX
NCT00211900 · Nabi Biopharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00211900 |
|---|---|
| Title | Evaluation of Manufacturing Lot of StaphVAX |
| Official title | A Phase 3, Multicenter, Open-Label, Historical Comparative Study to Evaluate Immunogenicity and Safety of a Commercial Lot of StaphVAX®, a Bivalent Staphylococcus Aureus Glycoconjugate Vaccine in Adults on Hemodialysis |
| Lead sponsor | Nabi Biopharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Staphylococcal Infections, Chronic Kidney Failure |
| Intervention type | Biological |
| Interventions | S. aureus Type 5 & 8 Capsular Polysaccharide Vaccine |
| Enrollment | 65 |
| Start date | Mar 1, 2005 |
| Primary completion | Aug 1, 2005 |
| Completion | Nov 1, 2005 |
| First posted | Sep 21, 2005 |
| Last update posted | Jan 4, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: